Canopy Growth Corp vs Oscar Health Inc — how do they compare? Canopy Growth Corp trades at $0.97 (market cap $398.46M), while Oscar Health Inc trades at $30.93 (market cap $9.37B). The key difference: Oscar Health Inc is far larger — about 23.5× Canopy Growth Corp's market cap, and Oscar Health Inc is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| CGC | OSCR | |
|---|---|---|
Market Cap | $398.46M | $9.37B |
Sector | Health | Health |
52-Week High | $1.92 | $32.18 |
52-Week Low | $0.86 | $10.85 |
Enterprise Value | $337.90M | $4.99B |
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.
The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.
OSCR trades at $31.60, up 3.47% today, showing strong momentum near recent highs. The stock exhibits a bullish technical outlook with positive moving average signals and support at $31. Recent Q1 2026 earnings beat expectations with $2.07 EPS versus $1.21 expected, though the company remains unprofitable with a -0.3% net margin. Revenue growth is robust, projected to increase from $11.70B in 2025 to $13.30B in 2026, while operating cash flow strengthens significantly.
The outlook is mixed: strong revenue growth and cash flow improvements support upside potential, but persistent losses and high P/B ratio of 5.63 pose risks. Analyst consensus is cautious with a $22.50 price target below current levels, though technical momentum suggests near-term strength. Key risks include execution on profitability goals and competitive pressures in the health insurance sector.
Trailing returns across standard periods
Latest headlines on both assets
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →